Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Revenue News

11/22/2024
BreakingCataractDry EyeLaserOcular CancerRevenue
Q3-2024 Ophthalmic Revenue Roundup for Immunocore, Harrow, Tarsus, Lumibird, and Ocular Therapeutix
Q3-2024 Ophthalmic Revenue Roundup for Immunocore, Harrow, Tarsus, Lumibird, and Ocular Therapeutix

UK-headquartered Immunocore reported Nov. 6 that its Q3-2024 net revenue from Kimmtrak (tebentafusp) was $80.2 million, a 28 percent increase over $62.6 million in Q3-2023. Regionally, Kimmtrak net...

11/15/2024
BreakingCataractChinaDry EyeGlaucomaIOLLaserRevenueSurgical
Q3-2024 Ophthalmic Revenue Roundup for Alcon, Hoya, RxSight, Sight Sciences, and Iridex
Q3-2024 Ophthalmic Revenue Roundup for Alcon, Hoya, RxSight, Sight Sciences, and Iridex

Alcon reported Nov. 12 that its Q3-2024 net sales totaled $2.4 billion, a 6 percent increase over $2.3 billion in Q3-2023. Surgical net sales for implantables, consumables, and equipment/other were...

11/8/2024
BreakingCataractCornealDry EyeGlaucomaLaserPharmaPresbyopiaRefractiveRetinaRevenueSurgical
Q3-2024 Ophthalmic Revenue Roundup for AbbVie, Apellis, Glaukos, STAAR, and Lensar
Q3-2024 Ophthalmic Revenue Roundup for AbbVie, Apellis, Glaukos, STAAR, and Lensar

AbbVie, of North Chicago, Illinois, reported Oct. 30 that its Q3-2024 eye care net revenue was $525 million, a 13.5 percent decline (-11.2 percent cc) from $605 million in Q3-2023. Restasis revenue...

11/1/2024
BreakingIOLPharmaRetinaRevenue
Q3-2024 Ophthalmic Revenue Roundup for Regeneron, Bausch + Lomb, and Novartis
Q3-2024 Ophthalmic Revenue Roundup for Regeneron, Bausch + Lomb, and Novartis

Regeneron of Tarrytown, New York, reported Oct. 31 that its Q3-2024 US revenue for Eylea (aflibercept) 2 mg and Eylea HD (a higher dose of aflibercept at 8 mg) was $1.54 billion, a 3 percent increa...

10/25/2024
BreakingIOLPharmaRetinaRevenueSurgical
Q3-2024 Ophthalmic Revenue Roundup for Roche and J&J Vision
Q3-2024 Ophthalmic Revenue Roundup for Roche and J&J Vision

Swiss company Roche reported Oct. 23 that Q3-2024 Vabysmo sales were CHF 1 billion ($1.15 billion, converted on Oct. 23, 2024), a 59 percent increase over CHF 656 million in Q3-2023. The company sa...

9/19/2024
NewsletterRetinaRevenue
Ophthalmic Company Revenue Up 2.6 Percent; Several Public Firms Report Record-High Quarters
Ophthalmic Company Revenue Up 2.6 Percent; Several Public Firms Report Record-High Quarters

Ophthalmic manufacturer revenue in Q2-2024 totaled $11.7 billion. Revenue increased 2.6 percent from the same quarter in 2023 and increased 5.9 percent from Q1-2024. The total includes Market Scope...

8/30/2024
BreakingCataractIOLRevenueSingle-UseSurgical
Alcon Reports Q2-2024 Net Sales of $2.5 Billion
Alcon Reports Q2-2024 Net Sales of $2.5 Billion

Alcon reported Aug. 20 that its Q2-2024 net sales totaled $2.5 billion, a record quarter for the company and a 3 percent increase (+6 percent cc) over $2.4 billion in Q2-2023. Surgical net sales fo...

8/21/2024
EuropeNewsletterRegulationRevenue
European Five Market Expected to Grow, Despite MDR Delays
European Five Market Expected to Grow, Despite MDR Delays

Device makers’ added costs for compliance with the new Medical Device Regulation (MDR) in the European Union (EU) will likely affect the mix of ophthalmic products and companies in the region. Howe...

8/16/2024
BiosimilarsBreakingCataractDiagnosticDry EyeGlaucomaLaserOcular CancerRefractiveRetinaRevenueSurgical
Q2-2024 Ophthalmic Revenue Roundup for AbbVie, Carl Zeiss Meditec, Amgen, STAAR, Astellas, Immunocore, Tarsus, Biogen, Lensar, and Iridex
Q2-2024 Ophthalmic Revenue Roundup for AbbVie, Carl Zeiss Meditec,  Amgen, STAAR, Astellas, Immunocore, Tarsus, Biogen, Lensar, and Iridex

AbbVie, of North Chicago, Illinois, reported July 25 that Q2-2024 net revenue for its eye care products totaled $533 million, a 13.3 percent decline (-10.9 percent cc) from $617 million in Q2-2023....

8/9/2024
BreakingCataractDry EyeGlaucomaIOLRetinaRevenueSurgical
Q2-2024 Ophthalmic Revenue Roundup for Hoya, Harrow, RxSight, Sight Sciences, Ocular Therapeutix, and EyePoint
Q2-2024 Ophthalmic Revenue Roundup for Hoya, Harrow, RxSight, Sight Sciences, Ocular Therapeutix, and EyePoint

Japan-based Hoya Corporation announced Aug. 1 that its medical care segment (IOLs, endoscopes, artificial bone) had revenue for the quarter ending June 30, 2024—the first quarter of its fiscal year...

8/2/2024
BreakingCornealDiagnosticDry EyeGlaucomaIOLLaserRetinaRevenueSurgical
Q2-2024 Ophthalmic Revenue Roundup for Regeneron, Roche, Bausch + Lomb, Novartis, and Four Others
Q2-2024 Ophthalmic Revenue Roundup for Regeneron, Roche, Bausch + Lomb, Novartis, and Four Others

Regeneron, of Tarrytown, New York, reported Aug. 1 that its Q2-2024 US revenue for Eylea was $1.53 billion, a 2 percent increase from $1.5 billion in Q2-2023. Eylea HD accounted for $304 million of...

7/19/2024
BreakingCataractIOLRevenueSurgical
J&J Vision Generates Q2-2024 Surgical Revenue of $367 Million
J&J Vision Generates Q2-2024 Surgical Revenue of $367 Million

J&J Vision’s Q2-2024 global surgical revenue totaled $367 million, a 0.5 percent decrease (1.2 percent increase in constant currency) from $369 million in Q2-2023, parent Johnson & Johnson, of New ...

6/24/2024
DeviceNewsletterPharmaRevenue
Ophthalmic Company Revenue Totals $11 Billion, a Drop of 0.2 Percent, in Q1-2024
Ophthalmic Company Revenue Totals $11 Billion, a Drop of 0.2 Percent, in Q1-2024

Ophthalmic manufacturer revenue in Q1-2024 totaled $11.0 billion. Revenue decreased 0.2 percent from the same quarter in 2023 and dropped 1.7 percent from Q4-2023. The total includes Market Scope e...

5/31/2024
BreakingCataractIOLOcular CancerRevenueSurgical
Q1-2024 Ophthalmic Revenue Roundup for Amgen, Hoya, and Immunocore
Q1-2024 Ophthalmic Revenue Roundup for Amgen, Hoya, and Immunocore

Amgen, of Thousand Oaks, California, reported May 2 that its Q1-2024 revenue from Tepezza was $424 million. The total consisted of $419 million in the US and $5 million outside the US. The company ...

5/24/2024
BiosimilarsBreakingDry EyeGlaucomaLaserRetinaRevenue
Q1-2024 Ophthalmic Revenue Roundup for AbbVie, Iridex, and Biogen
Q1-2024 Ophthalmic Revenue Roundup for AbbVie, Iridex, and Biogen

AbbVie, of North Chicago, Illinois, reported April 26 that its Q1-2024 eye care net revenue totaled $538 million, an 11.7 percent decline (-10.4 percent cc) from $608 million in Q1-2023. Restasis r...

5/17/2024
BreakingDiagnosticDry EyePharmaRetinaRevenueSurgical
Q1-2024 Ophthalmic Revenue Roundup for Alcon, Carl Zeiss Meditec, and Harrow
Q1-2024 Ophthalmic Revenue Roundup for Alcon, Carl Zeiss Meditec, and Harrow

Alcon reported May 13 that its Q1-2024 net sales were $2.4 billion, a 5 percent increase (+7 percent cc) over $2.3 billion in Q1-2023. Surgical net sales totaled $1.34 billion, consisting of $433 m...

5/10/2024
BreakingCataractDry EyeGlaucomaRefractiveRetinaRevenueSurgical
Q1-2024 Ophthalmic Revenue Roundup for Apellis, STAAR, RxSight, Tarsus, Sight Sciences, and Three Others
Q1-2024 Ophthalmic Revenue Roundup for Apellis, STAAR, RxSight, Tarsus, Sight Sciences, and Three Others

Apellis Pharmaceuticals, of Waltham, Massachusetts, reported May 7 that its Q1-2024 US net product revenue for Syfovre was $137.5 million, compared with $18.4 million in Q1-2023. Syfovre gained US ...

5/3/2024
BreakingCataractDry EyeGlaucomaLaserRevenueSurgical
Q1-2024 Ophthalmic Revenue Roundup for Bausch + Lomb, Glaukos, and Lumibird
Q1-2024 Ophthalmic Revenue Roundup for Bausch + Lomb, Glaukos, and Lumibird

Bausch + Lomb reported May 1 that its Q1-2024 revenue was $1.1 billion, an 18 percent increase (+20 percent cc) over $931 million in Q1-2023. Vision Care segment revenue in Q1-2024 was $635 million...

4/26/2024
BreakingGlaucomaPharmaRetinaRevenue
Q1-2024 Ophthalmic Revenue Roundup for Roche, Novartis, and Nicox
Q1-2024 Ophthalmic Revenue Roundup for Roche, Novartis, and Nicox

Swiss company Roche reported April 24 that Vabysmo sales in Q1-2024 were CHF 847 million ($926.5 million, calculated April 24, 2024), up from CHF 432 million (US $487 million) in Q1-2023. Vabysmo r...

4/19/2024
BreakingCataractIOLRevenueSurgical
J&J Vision Reports Q1-2024 Surgical Revenue of $348 Million
J&J Vision Reports Q1-2024 Surgical Revenue of $348 Million

J&J Vision’s Q1-2024 global surgical revenue totaled $348 million, up 0.3 percent (+1.1 percent cc) over $347 million in Q1-2023, parent Johnson & Johnson, of New Brunswick, New Jersey, reported Ap...

3/29/2024
BreakingDry EyeGlaucomaLaserRevenue
2023 Ophthalmic Revenue Roundup for Iridex and NovaBay
2023 Ophthalmic Revenue Roundup for Iridex and NovaBay

Iridex, of Mountain View, California, reported March 26 that its 2023 revenue was $51.9 million, a 9 percent decrease from $57 million in 2022. Cyclo G6 product revenue was $13.4 million, a 9 perce...

3/22/2024
BreakingDealsDry EyePharmaRevenueSurgical
2023 Ophthalmic Revenue Roundup for Harrow, Alimera Sciences, and EyePoint
2023 Ophthalmic Revenue Roundup for Harrow, Alimera Sciences, and EyePoint

Nashville, Tennessee-based Harrow reported March 19 that its 2023 revenue was $130.2 million, a 47 percent increase over $88.6 million in 2022. The company generated record quarterly revenue in Q4-...

3/21/2024
DeviceNewsletterPharmaRetinaRevenue
Ophthalmic Company Revenue in Q4-2023 Rises 0.4 Percent
Ophthalmic Company Revenue in Q4-2023 Rises 0.4 Percent

Ophthalmic manufacturer revenue in Q4-2023 totaled $11.2 billion. Revenue increased 0.4 percent from the same quarter in 2022 and increased 1.0 percent from Q3-2023. The total includes Market Scope...

3/15/2024
BreakingCataractDry EyeGlaucomaRevenueSurgical
2023 Ophthalmic Revenue Roundup for Sight Sciences and Ocular Therapeutix
2023 Ophthalmic Revenue Roundup for Sight Sciences and Ocular Therapeutix

Sight Sciences reported March 7 that it generated 2023 total revenue of $81.1 million, an increase of 14 percent over $71.3 million in 2022. Surgical glaucoma revenue in 2023 was $74.3 million, a 1...

3/8/2024
BiosimilarsBreakingIOLLaserOcular CancerRetinaRevenue
2023 Ophthalmic Revenue Roundup for Immunocore, RxSight, Lensar, and Biogen
2023 Ophthalmic Revenue Roundup for Immunocore, RxSight, Lensar, and Biogen

UK-headquartered Immunocore reported Feb. 28 that its 2023 net product revenue from Kimmtrak (tebentafusp) was $238.7 million, a 70 percent increase over $140.7 million in 2022. The 2023 total was ...

3/1/2024
BreakingCornealDry EyeGlaucomaIOLRefractiveRetinaRevenueSurgical
2023 Ophthalmic Revenue Roundup for Alcon, Bausch + Lomb, STAAR, Glaukos, Apellis, and Tarsus
2023 Ophthalmic Revenue Roundup for Alcon, Bausch + Lomb, STAAR, Glaukos, Apellis, and Tarsus

Alcon reported Feb. 27 that its full year 2023 net sales totaled $9.4 billion, an 8 percent increase (+10 percent cc) over $8.7 billion in 2022. Q4-2023 sales were $2.3 billion, an 8 percent increa...

2/16/2024
BreakingChinaIOLRefractiveRevenueSurgical
Ophthalmic Quarterly Revenue Roundup for Carl Zeiss Meditec and Hoya
Ophthalmic Quarterly Revenue Roundup for Carl Zeiss Meditec and Hoya

Carl Zeiss Meditec reported Feb. 9 that ophthalmology revenue for the last three months of 2023, its first quarter of fiscal year 2023/2024, totaled €351.1 million ($378.5 million, converted Feb. 9...

2/9/2024
BreakingDry EyeRetinaRevenue
2023 Ophthalmic Revenue Roundup for Regeneron, AbbVie, Amgen, and Astellas
2023 Ophthalmic Revenue Roundup for Regeneron, AbbVie, Amgen, and Astellas

Regeneron, of Tarrytown, New York, reported Feb. 2 that its 2023 US revenue for Eylea 2 mg (aflibercept 2 mg) and Eylea HD (aflibercept 8 mg) totaled $5.9 billion, a 6 percent decline from $6.3 bil...

2/2/2024
BreakingLaserPharmaRetinaRevenue
2023 Ophthalmic Revenue Roundup for Roche, Novartis, and Lumibird
2023 Ophthalmic Revenue Roundup for Roche, Novartis, and Lumibird

Swiss company Roche reported Feb. 1 that global sales of Vabysmo for 2023 were CHF 2.36 billion ($2.78 billion, converted Feb. 1, 2024), a 299 percent increase (+324 percent cc) over CHF 591 millio...

1/26/2024
BreakingGlaucomaIOLPharmaRevenueSurgical
2023 Ophthalmic Revenue Roundup for J&J Vision and Nicox
2023 Ophthalmic Revenue Roundup for J&J Vision and Nicox

Johnson & Johnson reported Jan. 23 that its full year 2023 global surgical vision revenue was $1.37 billion, a 4.9 percent increase (+5.8 percent cc) over $1.31 billion in 2022. Revenue was down 1....

12/15/2023
BreakingDiagnosticIOLRevenueSurgical
Carl Zeiss Meditec Reports Annual Ophthalmic Revenue of $1.67 Billion
Carl Zeiss Meditec Reports Annual Ophthalmic Revenue of $1.67 Billion

Carl Zeiss Meditec reported Dec. 12 that ophthalmology revenue for is full fiscal year 2022/2023, which ended Sept. 30, was €1.58 billion ($1.67 billion, converted Sept. 30), a 7.3 percent increase...

12/14/2023
CataractDeviceEarningsGlaucomaNewsletterPharmaRetinaRevenue
Ophthalmic Company Revenue Increases 3.4 Percent in Third Quarter of 2023
Ophthalmic Company Revenue Increases 3.4 Percent in Third Quarter of 2023

Ophthalmic manufacturer revenue in Q3-2023 totaled $11.1 billion. Revenue increased 3.4 percent from the same quarter in 2022 and decreased 2.7 percent from Q2-2023. The total includes Market Scope...

11/22/2023
BreakingLaserRevenueSurgical
Q3-2023 Ophthalmic Revenue Roundup for Alcon, Iridex, and Lensar
Q3-2023 Ophthalmic Revenue Roundup for Alcon, Iridex, and Lensar

Alcon reported Nov. 14 that its Q3-2023 net sales totaled $2.3 billion, an 8 percent increase (+9 percent cc) over $2.1 billion in Q3-2022. Surgical net sales for implantables, consumables, and equ...

11/17/2023
BreakingCataractDry EyeIOLOcular CancerPharmaRevenue
Q3-2023 Ophthalmic Revenue Roundup for Immunocore, Harrow, RxSight, and Three Others
Q3-2023 Ophthalmic Revenue Roundup for Immunocore, Harrow, RxSight, and Three Others

UK-headquartered Immunocore reported Nov. 7 that its Q3-2023 net revenue from Kimmtrak (tebentafusp) was £49.7 million ($60.7 million, converted at a rate of £1.00 to $1.2214), an increase of 9 per...

11/10/2023
BreakingDry EyeGlaucomaIOLLaserRevenue
Q3-2023 Ophthalmic Revenue Roundup for Hoya, Lumibird, Sight Sciences, and Ocular Therapeutix
Q3-2023 Ophthalmic Revenue Roundup for Hoya, Lumibird, Sight Sciences, and Ocular Therapeutix

Japan-based Hoya Corporation reported Oct. 31 that its medical segment (IOLs, endoscopes, and artificial bone) generated revenue for the third quarter of 2023—its fiscal year Q2-2023—of ¥33.5 billi...

11/3/2023
BreakingDry EyeGlaucomaPharmaRefractiveRetinaRevenueSurgical
Q3-2023 Ophthalmic Revenue Roundup for Regeneron, Bausch + Lomb, AbbVie, and Five Others
Q3-2023 Ophthalmic Revenue Roundup for Regeneron, Bausch +  Lomb, AbbVie, and Five Others

Regeneron of Tarrytown, New York, reported Nov. 2 that its Q3-2023 US revenue for Eylea (aflibercept) 2 mg and Eylea HD (a higher dose of aflibercept at 8 mg) was $1.49 billion, with Eylea HD accou...

10/27/2023
BiologicsBreakingDry EyeGlaucomaPharmaRetinaRevenueSurgical
Q3-2023 Ophthalmic Revenue Roundup for Roche, Novartis, J&J Vision, and Nicox
Q3-2023 Ophthalmic Revenue Roundup for Roche, Novartis, J&J Vision, and Nicox

Swiss company Roche reported Oct. 19 that Q3-2023 Vabysmo sales were CHF 656 million ($732 million, converted Oct. 19), a 309 percent increase over CHF 173 million in Q3-2022. Vabysmo was approved ...

9/21/2023
EarningsNewsletterRetinaRevenue
Ophthalmic Company Revenue in Q2-2023 Rises 1.5 Percent
Ophthalmic Company Revenue in Q2-2023  Rises 1.5 Percent

Ophthalmic manufacturer revenue in Q2-2023 totaled $11.4 billion. Most public companies reported above-average revenue in Q2-2023 compared with the past three years, while four public companies had...

9/8/2023
BreakingDry EyeRevenue
Viatris Reports Q2-2023 Tyrvaya Net Sales of $10.2 Million
Viatris Reports Q2-2023 Tyrvaya Net Sales of $10.2 Million

Viatris, of Pittsburgh, reported Aug. 7 that its Tyrvaya nasal spray for dry eye accounted for net sales of $10.2 million in Q2-2023. The prescription treatment posted net sales of $6.3 million in ...

9/1/2023
BiosimilarsBreakingRetinaRevenue
Q2-2023 Ophthalmic Revenue Roundup for Horizon and Biogen
Q2-2023 Ophthalmic Revenue Roundup for Horizon and Biogen

Horizon Therapeutics, of Dublin, Ireland, reported Aug. 8 that its Q2-2023 Tepezza net sales totaled $446 million, a 7 percent decrease from $479.8 million in Q2-2022. The company said expansion of...

8/25/2023
BreakingDiagnosticDry EyePresbyopiaRetinaRevenueSurgical
Q2-2023 Ophthalmic Revenue Roundup for AbbVie, Carl Zeiss Meditec, Alimera
Q2-2023 Ophthalmic Revenue Roundup for AbbVie, Carl Zeiss Meditec, Alimera

AbbVie, of North Chicago, Illinois, reported July 27 that Q2-2023 net revenue for its eye care products totaled $617 million, a 13.9 percent decline from $717 million in Q2-2022. Restasis revenue w...

8/18/2023
BreakingCataractGlaucomaLaserPharmaRevenueSurgical
Q2-2023 Ophthalmic Revenue Roundup for Alcon, Immunocore, Harrow, and Two Others
Q2-2023 Ophthalmic Revenue Roundup for Alcon, Immunocore, Harrow, and Two Others

Alcon reported Aug. 15 that its Q2-2023 net sales totaled $2.4 billion, a 9 percent increase (+12 percent cc) over $2.2 billion in Q2-2022. Surgical net sales for implantables, consumables, and equ...

8/10/2023
AllergyBreakingCataractGlaucomaIOLRevenueSurgical
Q2-2023 Ophthalmic Revenue Roundup for RxSight, LENSAR, Hoya, and Two Others
Q2-2023 Ophthalmic Revenue Roundup for RxSight, LENSAR, Hoya, and Two Others

Japan-based Hoya Corporation announced July 31 that its medical care segment (IOLs, endoscopes, artificial bone) had revenue for the quarter ending June 30, 2023—the first quarter of its fiscal yea...

8/4/2023
BreakingGlaucomaRefractiveRetinaRevenueSurgical
Q2-2023 Ophthalmic Revenue Roundup for Regeneron, Bausch + Lomb, STAAR, and Two Others
Q2-2023 Ophthalmic Revenue Roundup for Regeneron, Bausch + Lomb, STAAR, and Two Others

Regeneron, of Tarrytown, New York, reported Aug. 3 that its Q2-2023 US revenue for Eylea was $1.5 billion, a 7 decrease from $1.62 billion in Q2-2022. The company attributed the decline to a lower ...

7/28/2023
BreakingDry EyeGlaucomaIOLLaserRetinaRevenue
Q2-2023 Ophthalmic Revenue Roundup for Roche, Novartis, J&J Vision, and Two Others
Q2-2023 Ophthalmic Revenue Roundup for Roche, Novartis, J&J Vision, and Two Others

Swiss company Roche reported July 27 that Vabysmo sales for Q2-2023 were CHF 525 million ($606 million, converted July 27, 2023), a nearly 500 percent increase over CHF 88 million in Q2-2022. Roche...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more